{
    "clinical_study": {
        "@rank": "153305", 
        "brief_summary": {
            "textblock": "The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels\n      in the treatment of residual colorectal cancer following recent surgery."
        }, 
        "brief_title": "Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery", 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Disease Characteristics:\n\n          -  Patients with documented histologic and cytologic diagnosis of colon or rectal\n             malignancy\n\n          -  Patients with documented status post surgical resection of primary cancer or\n             metastases\n\n          -  Limited residual disease (i.e., CEA serum levels < 15 ng/mL and negative baseline CT\n             scans, or no lesion > 1 cm)\n\n        Prior/Concurrent Therapy:\n\n          -  Patients must have completed chemotherapeutic agents, biologic therapy, radiotherapy,\n             other investigational therapy for cancer, or surgical procedures at least six weeks\n             prior to study entry.\n\n          -  Patients must have recuperated from surgery and toxicities (as a result of previous\n             therapy) sufficiently prior to study entry\n\n          -  Biologic Therapy: Patients who have received a murine, chimeric, CDR-grafted\n             (humanized), or human IgG will be eligible provided pre-study evaluations demonstrate\n             no significant reactivity with hMN-14 IgG (i.e., HAHA)\n\n          -  Radiotherapy: No prior external beam irradiation to a field that includes more than\n             30% of the red marrow.  No prior radiation to maximal tolerable levels for any\n             critical organs (e.g., 3000 cGy for the liver; 2000 cGy for the lungs and kidneys)\n\n        Patient Characteristics/Inclusion Criteria:\n\n          -  Performance Status: Patients with Karnofsky performance status > 70%\n\n          -  Hematopoietic: ANC >/= 1.5 x 10/L; Hemoglobin >/= 10 g/dL; Platelets >/= 100 x 10/L\n\n          -  Renal: Serum Creatinine </= 1.5 x ULN\n\n          -  Hepatic: Serum Bilirubin </= 1.5 ULN; AST and ALT </= 2.5 x ULN; Alk Phosphatase </=\n             2.5 x ULN\n\n          -  Cardiovascular: Patients with LVEF >/= 50% by required MUGA/2D-ECHO tests\n\n          -  Pulmonary: Patients with DF and FEV1 >/= 60% by required Pulmonary Function Tests\n\n          -  Central Nervous System: Patients with known metastatic disease to the CNS are\n             excluded.\n\n          -  Other: Patients agreeing to use a medically effective method of contraception during\n             and for a period of three months after the treatment period. A pregnancy test will be\n             preformed on each premenopausal female of childbearing potential immediately prior to\n             entry into study.  Patients must understand and give written informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "July 12, 2002", 
        "id_info": {
            "nct_id": "NCT00041691", 
            "org_study_id": "IM-T-hMN14-06"
        }, 
        "intervention": {
            "intervention_name": "hMN14 (labetuzumab)", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Colorectal Cancer", 
            "Colon Cancer", 
            "Rectal Cancer", 
            "Colorectal Neoplasms", 
            "Colorectal Carcinoma", 
            "Colorectal Tumor"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Washington Hospital Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Virginia Mason Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I, Single Dose Escalating Study to Investigate the Tolerability, Pharmacokinetics and Dosimetry of 90 Y-Humanized MN-14 IgG in Colorectal Cancer Patients With Limited Residual Disease After Primary or Salvage Surgery", 
        "overall_official": [
            {
                "affiliation": "Immunomedics, Inc.", 
                "last_name": "Lauri Welles, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Immunomedics, Inc.", 
                "last_name": "Terence Rugg, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041691"
        }, 
        "source": "Immunomedics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Immunomedics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2003"
    }, 
    "geocoordinates": {
        "Virginia Mason Medical Center": "47.606 -122.332", 
        "Washington Hospital Center": "38.895 -77.036"
    }
}